1) The availability of the BIOLOGICAL RESOURCE is restricted to a RECIPIENT of a not-for profit organization for a not-for profit research. 2) For use of the BIOLOGICAL RESOURCE by a for-profit organization or by a not-for profit organization for for-profit research, the RECIPIENT must reach agreement on Terms and Conditions of use of it with the DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. 3) Co-authorship must be given to the depositor when the results using the cells are published.
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
16509
Oshima Y, Sano M, Kajiwara I, Ichimaru Y, Itaya T, Kuramochi T, Hayashi E, Kim J, Kitajima O, Masugi Y, Masamune A, Ijichi H, Ishii Y, Suzuki T.
Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinomaBr J Anaesth
2022
128(4):679-690
PubMed ID: 35120712
DOI: 10.1016/j.bja.2021.12.042
22431
Kajiwara I, Sano M, Ichimaru Y, Oshima Y, Kitajima O, Hao H, Masamune A, Kim J, Ishii Y, Ijichi H, Suzuki T.
Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effectsPain
2020
161(12):2909-2919
PubMed ID: 32694385
DOI: 10.1097/j.pain.0000000000001997
19848
Yamanaka T, Araki K, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Ishii N, Tsukagoshi M, Watanabe A, Harimoto N, Masamune A, Uojima H, Mizokami M, Ito K, Shirabe K.
Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancerCancer Sci
2024
Feb 6
PubMed ID: 38321872
DOI: 10.1111/cas.16087
22346
Tsunetoshi Y, Sanada F, Kanemoto Y, Shibata K, Masamune A, Taniyama Y, Yamamoto K, Morishita R.
A Role for Periostin Pathological Variants and Their Interaction with HSP70-1a in Promoting Pancreatic Cancer Progression and ChemoresistanceInt J Mol Sci
2024
25(23):13205
PubMed ID: 39684914
DOI: 10.3390/ijms252313205
19772
Itaya T, Sano M, Kajiwara I, Oshima Y, Kuramochi T, Kim J, Ichimaru Y, Kitajima O, Masamune A, Ijichi H, Ishii Y, Suzuki T.
Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancerPain
2023
164(7):1545-1554
PubMed ID: 36701124
DOI: 10.1097/j.pain.0000000000002852
22431
Kajiwara I, Sano M, Ichimaru Y, Oshima Y, Kitajima O, Hao H, Masamune A, Kim J, Ishii Y, Ijichi H, Suzuki T.
Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effectsPain
2020
161(12):2909-2919
PubMed ID: 32694385
DOI: 10.1097/j.pain.0000000000001997
6912
Ishii N, Araki K, Yokobori T, Hagiwara K, Gantumur D, Yamanaka T, Handa T, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Masamune A, Umezawa K, Kuwano H, Shirabe K.
Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts.Cancer Sci
2019
110(1):334-344
PubMed ID: 30353606
DOI: 10.1111/cas.13847